TY - JOUR
T1 - Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia :
T2 - A Post Hoc Analysis of Three Cohort Studies
AU - Moreno-García, Estela
AU - Puerta-Alcalde, Pedro
AU - Gariup, Giuseppe
AU - Fernández-Ruiz, Mario
AU - López Cortés, Luis Eduardo
AU - Cuervo, Guillermo
AU - Salavert, Miguel
AU - Merino, Paloma
AU - Machado, Marina
AU - Guinea, Jose
AU - García-Rodríguez, Julio
AU - Garnacho-Montero, Jose
AU - Cardozo, Celia
AU - Peman, Javier
AU - Montejo, Miguel
AU - Fortún, Jesús
AU - Almirante Gragera, Benito
AU - Castro, Carmen
AU - Rodríguez-Baño, Jesús
AU - Aguado, José María
AU - Martínez, Jose Alfredo
AU - Carratalà, Jordi
AU - Soriano, Alex
AU - Garcia-Vidal, Carolina
PY - 2021
Y1 - 2021
N2 - There are no clear criteria for antifungal de-escalation after initial empirical treatments. We hypothesized that early de-escalation (ED) (within 5 days) to fluconazole is safe in fluconazole-susceptible candidemia with controlled source of infection. This is a multicenter post hoc study that included consecutive patients from 3 prospective candidemia cohorts (2007-2016). The impact of ED and factors associated with mortality were assessed. Of 1023 candidemia episodes, 235 met inclusion criteria. Of these, 54 (23%) were classified as the ED group and 181 (77%) were classified as the non-ED group. ED was more common in catheter-related candidemia (51.9% vs 31.5%; P = .006) and episodes caused by Candida parapsilosis, yet it was less frequent in patients in the intensive care unit (24.1% vs 39.2%; P = .043), infections caused by Nakaseomyces glabrata (0% vs 9.9%; P = .016), and candidemia from an unknown source (24.1% vs 47%; P = .003). In the ED and non-ED groups, 30-day mortality was 11.1% and 29.8% (P = .006), respectively. Chronic obstructive pulmonary disease (odds ratio [OR], 3.97; 95% confidence interval [CI], 1.48-10.61), Pitt score > 2 (OR, 4.39; 95% CI, 1.94-9.20), unknown source of candidemia (OR, 2.59; 95% CI, 1.14-5.86), candidemia caused by Candida albicans (OR, 3.92; 95% CI, 1.48-10.61), and prior surgery (OR, 0.29; 95% CI, 0.08-0.97) were independent predictors of mortality. Similar results were found when a propensity score for receiving ED was incorporated into the model. ED had no significant impact on mortality (OR, 0.50; 95% CI, 0.16-1.53). Early de-escalation is a safe strategy in patients with candidemia caused by fluconazole-susceptible strains with controlled source of bloodstream infection and hemodynamic stability. These results are important to apply antifungal stewardship strategies. Early de-escalation (within 5 days of candidemia onset) was proven to be safe in episodes caused by fluconazole-susceptible strains with a controlled source of candidemia and hemodynamic stability. These results might help strengthen antifungal stewardship strategies.
AB - There are no clear criteria for antifungal de-escalation after initial empirical treatments. We hypothesized that early de-escalation (ED) (within 5 days) to fluconazole is safe in fluconazole-susceptible candidemia with controlled source of infection. This is a multicenter post hoc study that included consecutive patients from 3 prospective candidemia cohorts (2007-2016). The impact of ED and factors associated with mortality were assessed. Of 1023 candidemia episodes, 235 met inclusion criteria. Of these, 54 (23%) were classified as the ED group and 181 (77%) were classified as the non-ED group. ED was more common in catheter-related candidemia (51.9% vs 31.5%; P = .006) and episodes caused by Candida parapsilosis, yet it was less frequent in patients in the intensive care unit (24.1% vs 39.2%; P = .043), infections caused by Nakaseomyces glabrata (0% vs 9.9%; P = .016), and candidemia from an unknown source (24.1% vs 47%; P = .003). In the ED and non-ED groups, 30-day mortality was 11.1% and 29.8% (P = .006), respectively. Chronic obstructive pulmonary disease (odds ratio [OR], 3.97; 95% confidence interval [CI], 1.48-10.61), Pitt score > 2 (OR, 4.39; 95% CI, 1.94-9.20), unknown source of candidemia (OR, 2.59; 95% CI, 1.14-5.86), candidemia caused by Candida albicans (OR, 3.92; 95% CI, 1.48-10.61), and prior surgery (OR, 0.29; 95% CI, 0.08-0.97) were independent predictors of mortality. Similar results were found when a propensity score for receiving ED was incorporated into the model. ED had no significant impact on mortality (OR, 0.50; 95% CI, 0.16-1.53). Early de-escalation is a safe strategy in patients with candidemia caused by fluconazole-susceptible strains with controlled source of bloodstream infection and hemodynamic stability. These results are important to apply antifungal stewardship strategies. Early de-escalation (within 5 days of candidemia onset) was proven to be safe in episodes caused by fluconazole-susceptible strains with a controlled source of candidemia and hemodynamic stability. These results might help strengthen antifungal stewardship strategies.
KW - Antifungal
KW - Candidemia
KW - De-escalation
KW - Invasive candidiasis
KW - Outcome
UR - https://www.scopus.com/pages/publications/85116057487
U2 - 10.1093/ofid/ofab250
DO - 10.1093/ofid/ofab250
M3 - Article
C2 - 34104670
SN - 2328-8957
VL - 8
JO - Open Forum Infectious Diseases
JF - Open Forum Infectious Diseases
ER -